Skip to main content
Premium Trial:

Request an Annual Quote

Spartan Bio, TrimGen Sign Development, Distribution Pact

NEW YORK (GenomeWeb News) – Under a new strategic partnership, TrimGen will develop technology for Spartan Bioscience and Spartan will distribute TrimGen products in Canada, Ottawa-based Spartan said today.
 
TrimGen has agreed to develop real-time PCR reagents and kits for the Spartan DX device. Coupling the Spartan DX with TrimGen’s real-time PCR assays allows Spartan to offer “a complete solution for rapid DNA testing,” Spartan Bioscience CEO Paul Lem said in a statement.
 
TrimGen is focused on developing nucleic acid-based molecular diagnostics for leukemia, cancer, and infectious diseases.
 
Spartan is aimed at developing applications “where rapid and convenient DNA testing is particularly important, such as low-throughput research experiments and non-batched testing for infectious diseases.”

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.